HRP20100327T1 - Triciklički derivati n-heteroaril- karboksamida koji sadržavaju benzimidazolsku jedinicu, postupak za dobivanje istih i njihova terapijska upotreba - Google Patents
Triciklički derivati n-heteroaril- karboksamida koji sadržavaju benzimidazolsku jedinicu, postupak za dobivanje istih i njihova terapijska upotreba Download PDFInfo
- Publication number
- HRP20100327T1 HRP20100327T1 HR20100327T HRP20100327T HRP20100327T1 HR P20100327 T1 HRP20100327 T1 HR P20100327T1 HR 20100327 T HR20100327 T HR 20100327T HR P20100327 T HRP20100327 T HR P20100327T HR P20100327 T1 HRP20100327 T1 HR P20100327T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- cycloalkyl
- alkylene
- aryl
- formula
- Prior art date
Links
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 title claims abstract 9
- 238000000034 method Methods 0.000 title claims 3
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 46
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 125000003118 aryl group Chemical group 0.000 claims abstract 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 20
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 20
- 125000005843 halogen group Chemical group 0.000 claims abstract 17
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 16
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims abstract 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 12
- 125000004429 atom Chemical group 0.000 claims abstract 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- -1 C (O) NR4R5 Chemical group 0.000 claims abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 7
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract 6
- 125000001424 substituent group Chemical group 0.000 claims abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 5
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims abstract 4
- 125000005368 heteroarylthio group Chemical group 0.000 claims abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims abstract 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical group C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 125000005000 thioaryl group Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- VVOGMSXSBHJMRP-UHFFFAOYSA-N 2-(2-chlorophenyl)-1,3-dioxo-n-(7,8,9,10-tetrahydro-6h-azepino[1,2-a]benzimidazol-3-yl)isoindole-5-carboxamide Chemical compound ClC1=CC=CC=C1N1C(=O)C2=CC(C(=O)NC=3C=C4N=C5CCCCCN5C4=CC=3)=CC=C2C1=O VVOGMSXSBHJMRP-UHFFFAOYSA-N 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 231100000013 eye irritation Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 231100000017 mucous membrane irritation Toxicity 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Spoj, naznačen time što odgovara formuli (I) u kojoj: A je, zajedno s C-N vezom benzimidazolske jedinice s kojom je vezan, 4- do 7-člani monociklički heterocikl ili monociklički heteroaril, koji sadržava od jedan do tri heteroatoma odabrana od O, S i N, uključujući dušikov atom benzimidazolske jedinice; P je 8-, 9-, 10- ili 11-člani biciklički heterocikl ili biciklički heteroaril, koji sadržava od 1 do 6 heteroatoma odabranih od N, O i S; P je vezan za -C(Y)- skupinu preko ugljikovog atoma; pod uvjetom da, kad A je 7-člani zasićeni heterocikl, P nije 2,3-dihidro-1,4-benzodioksan skupina, 1-benzopiran-2-on skupina i izoindol skupina; R1 je od jedan do četiri atoma ili skupina, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena, i okso, tio, C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, ariloksi-C1-C6-alkil, heteroariloksi-C1-C6-alkil, aril-C1-C3-alkilenoksi-C1-C6-alkil, heteroaril-C1-C3-alkilenoksi-C1-C6-alkil, ariltio-C1-C6-alkil, heteroariltio-C1-C6-alkil, aril-C1-C3-alkilentio-C1-C6-alkil, heteroaril-C1-C3-alkilentio-C1-C6-alkil, C1-C6-alkoksi, C3-C7-cikloalkiloksi, C3-C7-cikloalkil-C1-C3-alkilenoksi, C1-C6-fluoralkoksi, cijano, C(O)NR4R5, nitro, NR4R5, C1-C6-tioalkil, C3-C7-cikloalkiltio, C3-C7-cikloalkil-C1-C3-alkilentio, -S(O)-C1-C6-alkil, -S(O)-C3-C7-cikloalkil, -S(O)-C1-C3-alkilen-C3-C7-cikloalkil, C1-C6-alkil-S(O)2-, C1-C6-fluoralkil-S(O)2-, C3-C7-cikloalkil-S(O)2-, C3-C7-cikloalkil-C1-C3-alkilen-S(O)2-, SO2NR4R5, SF5, NR6C(O)R7, NR6SO2R8, R4R5NC(O)-C1-C3-alkilen, aril, heteroaril, aril-C1-C5-alkilen, heteroaril-C1-C5-alkilen, ariloksi, ariltio, heteroariloksi ili heteroariltio skupine; spomenute heteroaril ili aril skupine sa R1 su po potrebi supstituirane s jednim ili više supstituenata R9, koji mogu biti identični ili različiti jedan od drugog; pod uvjetom da, kad R1 je vezan za atom dušika sa P, onda je R1 različit od atoma halogena, i od okso, tio, cijano, nitro, SF5, NR4R5, C1-C6-tioalkil, tioaril, tioheteroaril, C1-C6-alkoksi, ariloksi, heteroariloksi, -NR6COR7 i NR6SO2R8 skupine; Y je atom kisika ili sumpora; R2 je atom vodika, atom halogena, ili C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil ili C1-C6-alkoksi skupina; R3 je od jedan do tri atoma ili skupine, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena, i C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, hidroksil, C1-C6-alkoksi, C3-C7-cikloalkiloksi ili C3-C7-cikloalkil-C1-C3-alkilenoksi skupine, kad je R3 vezan preko ugljikovog atoma; iliR3 je od jedan do dva atoma ili skupine, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena, i C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, aril-C(O)-, C1-C6-alkil-C(O)-, C3-C7-cikloalkil-C(O)-, C3-C7-cikloalkil-C1-C3-alkilen-C(O)-, C1-C6-fluoralkil-C(O)-, aril-S(O)2-, C1-C6-alkil-S(O)2-, C1-C6-fluoralkil-S(O)2-, C3-C
Claims (16)
1. Spoj, naznačen time što odgovara formuli (I)
[image]
u kojoj:
A je, zajedno s C-N vezom benzimidazolske jedinice s kojom je vezan, 4- do 7-člani monociklički heterocikl ili monociklički heteroaril, koji sadržava od jedan do tri heteroatoma odabrana od O, S i N, uključujući dušikov atom benzimidazolske jedinice;
P je 8-, 9-, 10- ili 11-člani biciklički heterocikl ili biciklički heteroaril, koji sadržava od 1 do 6 heteroatoma odabranih od N, O i S; P je vezan za -C(Y)- skupinu preko ugljikovog atoma;
pod uvjetom da, kad A je 7-člani zasićeni heterocikl, P nije 2,3-dihidro-1,4-benzodioksan skupina, 1-benzopiran-2-on skupina i izoindol skupina;
R1 je od jedan do četiri atoma ili skupina, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena, i okso, tio, C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, ariloksi-C1-C6-alkil, heteroariloksi-C1-C6-alkil, aril-C1-C3-alkilenoksi-C1-C6-alkil, heteroaril-C1-C3-alkilenoksi-C1-C6-alkil, ariltio-C1-C6-alkil, heteroariltio-C1-C6-alkil, aril-C1-C3-alkilentio-C1-C6-alkil, heteroaril-C1-C3-alkilentio-C1-C6-alkil, C1-C6-alkoksi, C3-C7-cikloalkiloksi, C3-C7-cikloalkil-C1-C3-alkilenoksi, C1-C6-fluoralkoksi, cijano, C(O)NR4R5, nitro, NR4R5, C1-C6-tioalkil, C3-C7-cikloalkiltio, C3-C7-cikloalkil-C1-C3-alkilentio, -S(O)-C1-C6-alkil, -S(O)-C3-C7-cikloalkil, -S(O)-C1-C3-alkilen-C3-C7-cikloalkil, C1-C6-alkil-S(O)2-, C1-C6-fluoralkil-S(O)2-, C3-C7-cikloalkil-S(O)2-, C3-C7-cikloalkil-C1-C3-alkilen-S(O)2-, SO2NR4R5, SF5, NR6C(O)R7, NR6SO2R8, R4R5NC(O)-C1-C3-alkilen, aril, heteroaril, aril-C1-C5-alkilen, heteroaril-C1-C5-alkilen, ariloksi, ariltio, heteroariloksi ili heteroariltio skupine;
spomenute heteroaril ili aril skupine sa R1 su po potrebi supstituirane s jednim ili više supstituenata R9, koji mogu biti identični ili različiti jedan od drugog;
pod uvjetom da, kad R1 je vezan za atom dušika sa P, onda je R1 različit od atoma halogena, i od okso, tio, cijano, nitro, SF5, NR4R5, C1-C6-tioalkil, tioaril, tioheteroaril, C1-C6-alkoksi, ariloksi, heteroariloksi, -NR6COR7 i NR6SO2R8 skupine;
Y je atom kisika ili sumpora;
R2 je atom vodika, atom halogena, ili C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil ili C1-C6-alkoksi skupina;
R3 je od jedan do tri atoma ili skupine, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena, i C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, hidroksil, C1-C6-alkoksi, C3-C7-cikloalkiloksi ili C3-C7-cikloalkil-C1-C3-alkilenoksi skupine, kad je R3 vezan preko ugljikovog atoma;
ili
R3 je od jedan do dva atoma ili skupine, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena, i C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, aril-C(O)-, C1-C6-alkil-C(O)-, C3-C7-cikloalkil-C(O)-, C3-C7-cikloalkil-C1-C3-alkilen-C(O)-, C1-C6-fluoralkil-C(O)-, aril-S(O)2-, C1-C6-alkil-S(O)2-, C1-C6-fluoralkil-S(O)2-, C3-C7-cikloalkil-S(O)2-, C3-C7-cikloalkil-C1-C3-alkilen-S(O)2-, C1-C6-alkil-O-C(O)-, aril-C1-C3-alkil-O-C(O)-, C3-C7-cikloalkil-O-C(O)-, C3-C7-cikloalkil-C1-C3-alkilen-O-C(O)-, C1-C6-fluoralkil-O-C(O)-, aril-O-C(O)- ili heteroaril-O-C(O)- skupine, kad je R3 vezan preko atoma dušika;
R4 i R5 su, nezavisno jedan od drugoga, atom vodika ili C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, aril-C1-C5-alkilen ili aril skupina; ili R4 i R5 formiraju, zajedno s atomom dušika za koji su vezani, azetidin, pirolidin, piperidin, azepin, morfolin, tiomorfolin, piperazin ili homopiperazin skupinu, NR4R5 skupina je po potrebi supstituirana s C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, aril-C1-C6-alkilen, aril, heteroaril, aril-S(O)2-, C1-C6-alkil-S(O)2-, C1-C6-fluoralkil-S(O)2-, C3-C7-cikloalkil-S(O)2-, C3-C7-cikloalkil-C1-C3-alkilen-S(O)2-, aril-C(O)-, C1-C6-alkil-C(O)-, C3-C7-cikloalkil-C(O)-, C3-C7-cikloalkil-C1-C3-alkilen-C(O)-, C1-C6-fluoralkil-C(O)-, hidroksil, C1-C6-alkiloksi, C1-C6-fluoralkil, ariloksi-C1-C6-alkilen, ariloksi, heteroariloksi-C1-C6-alkilen ili heteroariloksi skupinom;
R6 i R7 su, nezavisno jedan od drugoga, atom vodika, ili C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, aril-C1-C6-alkilen ili aril skupina; ili R6 i R7 zajedno formiraju 4- do 7-člani laktam koji sadržava atom dušika i C(O) skupinu koja ih veže;
R8 je C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, aril-C1-C6-alkilen ili aril skupina;
ili R6 i R8 zajedno formiraju 4- do 7-člani sultam koji sadržava atom dušika i S(O)2 skupinu koja ih veže;
R9 je atom halogena, ili C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, C1-C6-alkoksi, C1-C6-fluoralkoksi, nitro, cijano, NR4R5, R4R5N-C1-C3-alkilen, aril, heteroaril, ariloksi, ariltio, heteroariloksi ili heteroariltio skupina, spomenute heteroaril ili aril skupine su po potrebi supstituirane s jednim ili više supstituenata odabranih od atoma halogena, i C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, C1-C6-alkoksi, C1-C6-fluor-alkoksi, nitro, cijano, NR4R5 ili R4R5NC1-C3-alkilen skupine;
atom(i) sumpora heterocikla A mogu biti u oksidiranom obliku (S(O) ili S(O)2);
atom(i) dušika mogu biti u oksidiranom obliku (N-oksid); u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata;
2-(2-klorfenil)-1,3-diokso-N-(7,8,9,10-tetrahidro-6H-azepino[1,2-a]benzimidazol-3-il)izoindolin-5-karboksamid je isključen.
2. Spoj iz izuma prema zahtjevu 1, naznačen time što odgovara formuli (II):
[image]
u kojoj:
X je atom ugljika ili atom dušika; spomenuti X su identični ili različiti jedan od drugog i broj X = N nije veći od 2;
R1, R2, R3, Y i A su kao što je definirano u formuli (I) prema zahtjevu 1, moguće je da R1 bude vezan za 6-element ili 5-element jedinicu bicikla;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
3. Spoj iz izuma prema zahtjevu 1 ili 2, naznačen time što odgovara formuli (III):
[image]
u kojoj:
R1a je jedan ili više atoma ili skupina, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena ili C1-C6-alkil, C1-C6-fluoralkil, C1-C6-alkoksi, C1-C6-tioalkil, C1-C6-alkil-S(O)2-, NR4R5 ili nitro skupine;
R1b je atom vodika, ili C1-C6-alkil, heteroariloksi-C1-C6-alkil, aril-C1-C3-alkilenoksi-C1-C6-alkil, R4R5NC(O)-C1-C3-alkilen, aril, heteroaril, aril-C1-C6-alkilen ili heteroaril-C1-C6-alkilen skupina;
spomenute heteroaril ili aril skupine sa R1b, su po potrebi supstituirane s jednim ili više supstituenata R9, koji mogu biti identični ili različiti jedan od drugog;
R9 je atom halogena ili C1-C6-alkil, C1-C6-alkoksi, C1-C6-fluoralkil, aril, heteroaril, NR4R5 ili ariltio skupina, spomenute heteroaril ili aril skupine su po potrebi supstituirane s jednim ili više supstituenata odabranih od atoma halogena, i C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkilen, C1-C6-fluoralkil, C1-C6-alkoksi, C1-C6-fluoralkoksi, nitro, cijano ili R4R5N-C1-C3-alkilen skupine;
R2, R3, R4, R5, A, X i Y su kao što je definirano u formuli (II) prema zahtjevu 2;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
4. Spoj iz izuma prema bilo kojem od zahtjeva 1 do 3, naznačen time što odgovara formuli (IV):
[image]
u kojoj W je triciklički heterocikl ili triciklički heteroaril odabran od:
[image]
[image]
[image]
[image]
[image]
R1, R2, R3, P i Y su kao što je definirano u formuli (I) prema zahtjevu 1;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
5. Spoj iz izuma prema bilo kojem od zahtjeva 1 do 4, naznačen time što odgovara formuli (V)
[image]
u kojoj:
R1, R2, R3, A i P su kao što je definirano u formuli (I) prema zahtjevu 1;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
6. Spoj iz izuma prema bilo kojem od zahtjeva 1 do 5, naznačen time što odgovara formuli (V)
[image]
u kojoj:
R2 je atom vodika, ili C1-C6-alkil ili C1-C6-alkoksi skupina;
R3 je od jedan do tri atoma ili skupine, koje mogu biti identične ili različite, odabrane od atoma vodika, i C1-C6-alkil, C1-C6-alkoksi ili hidroksil skupine, kad je R3 vezan preko ugljikovog atoma;
ili
R3 je od jedan do dva atoma ili skupine, koje mogu biti identične ili različite, odabrane od atoma vodika, i C1-C6-alkil, C1-C6-alkil-O-C(O)- ili aril-C1-C3-alkil-O-C(O)- skupine, kad je R3 vezan preko atoma dušika;
R1, A i P su kao što je definirano u formuli (I) prema zahtjevu 1;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
7. Spoj iz izuma prema bilo kojem od zahtjeva 1 do 6, naznačen time što odgovara formuli (V)
[image]
u kojoj:
A je, zajedno s C-N vezom benzimidazolske jedinice s kojom je vezan, 5- do 7-člani monociklički heterocikl ili monociklički heteroaril koji sadržava od jedan do tri heteroatoma odabrana od O, S i N, uključujući dušikov atom benzimidazolske jedinice;
R1, R2, R3 i P su kao što je definirano u formuli (I) prema zahtjevu 1;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
8. Spoj iz izuma prema bilo kojem od zahtjeva 1 do 7, naznačen time što odgovara formuli (Va):
[image]
u kojoj
A je, s C-N vezom benzimidazolske jedinice s kojom je kondenziran, 5- do 7-člani monociklički heterocikl ili monociklički heteroaril koji sadržava jedan ili dva heteroatoma odabrana od O, S i N, uključujući dušikov atom benzimidazolske jedinice;
X je atom ugljika ili atom dušika; spomenuti X su identični ili različiti jedan od drugog i broj X = N nije veći od 1;
R1a je jedan ili više atoma ili skupina, koje mogu biti identične ili različite, odabrane od atoma vodika, atoma halogena ili C1-C6-alkil skupine, C1-C6-fluoralkil skupine, C1-C6-alkoksi skupine, C1-C6-tioalkil skupine, C1-C6-alkil-S(O)2- skupine, NR4R5 skupine ili nitro skupine;
R1b je atom vodika, ili C1-C6-alkil, heteroariloksi-C1-C6-alkil, aril-C1-C3-alkilenoksi-C1-C6-alkil, R4R5NC(O)-C1-C3-alkilen, aril, heteroaril, aril-C1-C6-alkilen ili heteroaril-C1-C6-alkilen skupina;
spomenute heteroaril ili aril skupine na R1b su po potrebi supstituirane s jednim ili više supstituenata R9, koji mogu biti identični ili različiti jedan od drugog;
R2 je atom vodika;
R3 je atom ili skupina odabrana od atoma vodika, C1-C6-alkil skupine, C1-C6-alkoksi skupine, ili hidroksil skupine, kad je R3 vezan preko ugljikovog atoma;
ili
R3 je atom ili skupina odabrana od atoma vodika, C1-C6-alkil skupine i C1-C6-alkil-O-C(O)- skupine, kad je R3 vezan preko atoma dušika;
R4 i R5 su, nezavisno jedan od drugoga, C1-C6-alkil skupina;
ili R4 i R5 formiraju, zajedno s atomom dušika za koji su vezani, pirolidin ili morfolin skupinu;
R9 je atom halogena ili C1-C6-alkil, C1-C6-alkoksi, C1-C6-fluoralkil, aril, heteroaril, NR4R5, ili ariltio skupina, spomenute aril skupine su po potrebi supstituirane s jednom ili više C1-C6-alkil skupina;
u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
9. Spoj iz izuma prema bilo kojem od zahtjeva 1 do 8, naznačen time što odgovara formuli (I) u kojoj su istovremeno R1 i/ili R2 i/ili R3, i/ili A, i/ili P i/ili Y kao što je definirano u zahtjevima 1 do 8; u obliku baze ili adicijske soli s kiselinom, i također u obliku hidrata ili solvata.
10. Postupak za dobivanje spoja formule (I) prema bilo kojem od zahtjeva 1 do 9, naznačen time što spoj formule (VI):
[image]
u kojoj P, R1 i Y su kao što je definirano u formuli (I) prema zahtjevu 1 i B je C1-C6-alkoksi, C3-C7-cikloalkiloksi, C3-C7-cikloalkil-C1-C3-alkilenoksi ili aril-C1-C3-alkilenoksi skupina, s amidom spoja formule (VII):
[image]
u kojoj A, R2 i R3 su kao što je definirano u formuli (I) prema zahtjevu 1, uz refluks otapala, amid spoja formule (VII) se pripravlja prethodnim djelovanjem trimetilaluminija na amine formule (VII).
11. Postupak za dobivanje spoja formule (I) prema bilo kojem od zahtjeva 1 do 9, naznačen time što spoj formule (VI):
[image]
u kojoj P, R1 i Y su kao što je definirano u formuli (I) prema zahtjevu 1 i B je hidroksil skupina, se prevodi u kiselinski klorid djelovanjem tionil klorida uz refluks otapala, i zatim time što dobiveni spoj formule (VI), u kojoj P, R1 i Y su kao što je definirano u formuli (I) prema zahtjevu 1 i B je atom klora, reagira, u prisutnosti baze, sa spojem formule (VII):
[image]
u kojoj A, R2 i R3 su kao što je definirano u formuli (I) prema zahtjevu 1;
ili također time što se reakcija spajanja izvodi između spoja formule (VI), u kojoj P, R1 i Y su kao što je definirano u formuli (I) prema zahtjevu 1 i B je hidroksil skupina, i spoja formule (VII) u kojoj A, R2 i R3 su kao što je definirano u formuli (I) prema zahtjevu 1, u prisutnosti sredstva za spajanje i baze, u otapalu.
12. Spoj, naznačen time što ima formulu (VIIa), (VIIb), (VIIc), (VIId), (VIIe), (VIIf), (VIIg), (VIIh), (VIIi), (VIIj), VIIk), (VIIl), (VIIm), (VIIn):
[image]
[image]
[image]
[image]
13. Lijek, naznačen time što sadržava najmanje jedan spoj formule (I) prema bilo kojem od zahtjeva 1 do 9, ili adicijsku sol ovog spoja s farmaceutski prihvatljivom kiselinom, ili također hidrat ili solvat spoja formule (I).
14. Farmaceutski pripravak, naznačen time što sadržava najmanje jedan spoj formule (I) prema bilo kojem od zahtjeva 1 do 9, ili farmaceutski prihvatljivu sol, hidrat ili solvat ovog spoja, i također najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo.
15. Upotreba spoja formule (I) prema bilo kojem od zahtjeva 1 do 9, naznačena time što se upotrebljava za dobivanje lijeka za upotrebu u prevenciji ili liječenju patologija u koje su uključeni receptori tipa TPPV1.
16. Upotreba spoja formule (I) prema bilo kojem od zahtjeva 1 do 9, naznačena time što se upotrebljava za dobivanje lijeka za upotrebu u sprečavanju ili liječenju boli, upale, metaboličkih poremećaja, uroloških poremećaja, ginekoloških poremećaja, gastrointestinalnih poremećaja, respiratornih poremećaja, psorijaze, svrbeža, kožnih, očnih ili mukoznih iritacija, herpesa, herpes zostera, multiple skleroze i depresije.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0601007A FR2897061B1 (fr) | 2006-02-03 | 2006-02-03 | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
PCT/FR2007/000183 WO2007088277A1 (fr) | 2006-02-03 | 2007-02-01 | Dérivés de ν-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur préparation et leur application en thérapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100327T1 true HRP20100327T1 (hr) | 2010-08-31 |
Family
ID=36954977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100327T HRP20100327T1 (hr) | 2006-02-03 | 2010-06-07 | Triciklički derivati n-heteroaril- karboksamida koji sadržavaju benzimidazolsku jedinicu, postupak za dobivanje istih i njihova terapijska upotreba |
Country Status (33)
Country | Link |
---|---|
US (2) | US8143248B2 (hr) |
EP (1) | EP1987010B1 (hr) |
JP (1) | JP5136938B2 (hr) |
KR (1) | KR20080090495A (hr) |
CN (1) | CN101379041B (hr) |
AR (1) | AR059279A1 (hr) |
AT (1) | ATE463484T1 (hr) |
AU (1) | AU2007211399B2 (hr) |
BR (1) | BRPI0710480A2 (hr) |
CA (1) | CA2637333C (hr) |
CY (1) | CY1110168T1 (hr) |
DE (1) | DE602007005779D1 (hr) |
DK (1) | DK1987010T3 (hr) |
DO (1) | DOP2007000022A (hr) |
EA (1) | EA014450B1 (hr) |
ES (1) | ES2344087T3 (hr) |
FR (1) | FR2897061B1 (hr) |
HK (1) | HK1129670A1 (hr) |
HR (1) | HRP20100327T1 (hr) |
IL (1) | IL192648A (hr) |
JO (1) | JO2602B1 (hr) |
MA (1) | MA30229B1 (hr) |
NO (1) | NO20083520L (hr) |
NZ (1) | NZ569669A (hr) |
PE (1) | PE20071325A1 (hr) |
PL (1) | PL1987010T3 (hr) |
PT (1) | PT1987010E (hr) |
RS (1) | RS51366B (hr) |
SI (1) | SI1987010T1 (hr) |
TW (1) | TWI401256B (hr) |
UY (1) | UY30130A1 (hr) |
WO (1) | WO2007088277A1 (hr) |
ZA (1) | ZA200806139B (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2888848B1 (fr) * | 2005-07-22 | 2007-09-28 | Sanofi Aventis Sa | Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
FR2911605B1 (fr) | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique |
FR2911604B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
FR2919610B1 (fr) * | 2007-08-02 | 2009-10-16 | Sanofi Aventis Sa | Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique |
FR2926554B1 (fr) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
FR2926555B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
FR2926553B1 (fr) * | 2008-01-23 | 2010-02-19 | Sanofi Aventis | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
WO2010005528A2 (en) * | 2008-06-30 | 2010-01-14 | Ironwood Pharmaceuticals Incorporated | Pyrrolopyridine carboxylic acid derivatives |
EP2352501B1 (en) * | 2008-11-03 | 2014-01-01 | ChemoCentryx, Inc. | Compounds for use in the treatment of osteoporosis |
EP2396327A1 (en) | 2009-02-11 | 2011-12-21 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
US20120172350A1 (en) * | 2009-09-11 | 2012-07-05 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
EP2565194A4 (en) * | 2010-04-27 | 2013-09-11 | Astellas Pharma Inc | Imidazo [1,2-A] pyridine |
PT2825542T (pt) * | 2012-03-16 | 2016-12-20 | Vitae Pharmaceuticals Inc | Modeladores do recetor x do fígado |
US9006244B2 (en) | 2012-03-16 | 2015-04-14 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
SG11201408395WA (en) | 2012-06-18 | 2015-01-29 | Dart Neuroscience Cayman Ltd | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
ES2809208T3 (es) * | 2015-06-25 | 2021-03-03 | Promega Corp | Compuestos de tienopirrol y usos de los mismos como inhibidores de luciferasas procedentes de Oplophorus |
US20200039961A1 (en) * | 2016-09-30 | 2020-02-06 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
JP7161475B2 (ja) | 2016-12-28 | 2022-10-26 | プロメガ コーポレイション | 官能化nanoluc阻害剤 |
WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
CN109761974B (zh) * | 2019-01-21 | 2021-05-14 | 河南大学 | 1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚类TRPV1拮抗剂及其应用 |
MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519605A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
CN114276354B (zh) * | 2022-01-07 | 2023-06-02 | 中山大学 | 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用 |
CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037274A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
WO2004007495A1 (ja) * | 2002-07-11 | 2004-01-22 | Takeda Pharmaceutical Company Limited | ピロロピリジン誘導体およびその用途 |
WO2004069792A2 (en) * | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid vr1 receptor |
GB0322016D0 (en) * | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
BRPI0513286A (pt) * | 2004-07-15 | 2008-05-06 | Japan Tobacco Inc | compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos |
-
2006
- 2006-02-03 FR FR0601007A patent/FR2897061B1/fr not_active Expired - Fee Related
-
2007
- 2007-01-30 PE PE2007000106A patent/PE20071325A1/es not_active Application Discontinuation
- 2007-01-31 TW TW096103550A patent/TWI401256B/zh not_active IP Right Cessation
- 2007-02-01 WO PCT/FR2007/000183 patent/WO2007088277A1/fr active Application Filing
- 2007-02-01 CN CN2007800042835A patent/CN101379041B/zh not_active Expired - Fee Related
- 2007-02-01 DK DK07730900.3T patent/DK1987010T3/da active
- 2007-02-01 ES ES07730900T patent/ES2344087T3/es active Active
- 2007-02-01 EP EP07730900A patent/EP1987010B1/fr active Active
- 2007-02-01 RS RSP-2010/0301A patent/RS51366B/en unknown
- 2007-02-01 AT AT07730900T patent/ATE463484T1/de active
- 2007-02-01 ZA ZA200806139A patent/ZA200806139B/xx unknown
- 2007-02-01 CA CA2637333A patent/CA2637333C/fr not_active Expired - Fee Related
- 2007-02-01 NZ NZ569669A patent/NZ569669A/en not_active IP Right Cessation
- 2007-02-01 JO JO200729A patent/JO2602B1/en active
- 2007-02-01 SI SI200730254T patent/SI1987010T1/sl unknown
- 2007-02-01 AR ARP070100426A patent/AR059279A1/es not_active Application Discontinuation
- 2007-02-01 JP JP2008552848A patent/JP5136938B2/ja not_active Expired - Fee Related
- 2007-02-01 PT PT07730900T patent/PT1987010E/pt unknown
- 2007-02-01 DO DO2007000022A patent/DOP2007000022A/es unknown
- 2007-02-01 PL PL07730900T patent/PL1987010T3/pl unknown
- 2007-02-01 EA EA200870226A patent/EA014450B1/ru not_active IP Right Cessation
- 2007-02-01 DE DE602007005779T patent/DE602007005779D1/de active Active
- 2007-02-01 BR BRPI0710480-4A patent/BRPI0710480A2/pt not_active IP Right Cessation
- 2007-02-01 KR KR1020087019041A patent/KR20080090495A/ko not_active Application Discontinuation
- 2007-02-01 AU AU2007211399A patent/AU2007211399B2/en not_active Ceased
- 2007-02-02 UY UY30130A patent/UY30130A1/es not_active Application Discontinuation
-
2008
- 2008-07-06 IL IL192648A patent/IL192648A/en not_active IP Right Cessation
- 2008-08-01 US US12/184,437 patent/US8143248B2/en not_active Expired - Fee Related
- 2008-08-13 NO NO20083520A patent/NO20083520L/no not_active Application Discontinuation
- 2008-08-26 MA MA31193A patent/MA30229B1/fr unknown
-
2009
- 2009-08-26 HK HK09107854.1A patent/HK1129670A1/xx not_active IP Right Cessation
-
2010
- 2010-06-07 HR HR20100327T patent/HRP20100327T1/hr unknown
- 2010-07-01 CY CY20101100609T patent/CY1110168T1/el unknown
-
2012
- 2012-01-24 US US13/357,015 patent/US8288376B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100327T1 (hr) | Triciklički derivati n-heteroaril- karboksamida koji sadržavaju benzimidazolsku jedinicu, postupak za dobivanje istih i njihova terapijska upotreba | |
Schneider et al. | Dopamine autoreceptor agonists: resolution and pharmacological activity of 2, 6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine | |
CN105814050B (zh) | 用作tnf活性调节剂的吡唑并吡啶衍生物 | |
TWI375673B (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors | |
US7544698B2 (en) | Indoles and benzoimidazoles as modulators of the histamine H4 receptor | |
CN101730699A (zh) | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 | |
CA3058639A1 (en) | Methods of using ehmt2 inhibitors | |
CN101534824A (zh) | 作为化学活素受体拮抗剂的氨基吡咯烷 | |
CN102164604A (zh) | 用作激酶调节剂的稠合杂环化合物 | |
CN109415336A (zh) | Mdm2蛋白质降解剂 | |
KR20190017948A (ko) | 항균제로서의 헤테로고리 화합물 | |
JP2021524440A (ja) | ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物 | |
WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
HRP20100076T1 (hr) | Heterociklički supstituirani fenil metanoni kao inhibitori glicin transportera 1 | |
MX2007008606A (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a. | |
CN107949384A (zh) | 毒蕈碱激动剂 | |
BR112016026150B1 (pt) | compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer | |
CN104903301A (zh) | 可用于调节IL-12、IL-23和/或IFNα的烷基酰胺取代的嘧啶化合物 | |
JP2009515849A (ja) | キナーゼ阻害剤としてのピロロピリジン | |
BR112016026951B1 (pt) | Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas | |
CN108794486A (zh) | 稠环基酮类衍生物、其制备方法及其在医药上的应用 | |
PT98768B (pt) | Processo de preparacao de derivados de piperazinilo e de composicoes farmaceuticas que os contem | |
HU204815B (en) | Process for producing 2-(1-piperazinyl)-4-phenyl-cycloalkanepyrimidine derivatives and pharmaceutical compositions comprising such compounds | |
HRP20100150T1 (hr) | N-(arilalkil)-1h-pirolopiridin-2-karboksamidni derivati, njihovo dobivanje i upotreba | |
RU2008110945A (ru) | N-оксиды как пролекарства производных пиперазина и пиперидина |